eioc®

Excellence in Oncology Care

13 - 15 November, 2026

InterContinental Dubai Festival City, UAE

61 CME Hours
Awarded by
هيئة الصحة بدبي
DUBAI HEALTH AUTHORITY

Delegates can earn maximum **18 CME** Hours based on attendance across **3 days**

CONFERENCE BOOKLET

IN CONJUNCTION WITH
APMEA ONCOLOGY MOLECULAR TUMOR BOARD

CONGRESS SECRETARIAT
إندكس INDEX CONFERENCES & EXHIBITIONS

cancercongress.ae

ACCESS.

COLLABORATE.

EDUCATE.

TABLE OF CONTENTS.

Welcome Message 04

EIOC Leadership 05

Meet the Faculty 08

Program at a Glance 24

Day 1 - Agenda 26

Day 2 - Agenda 40

Day 3 - Agenda 50

Our Sponsors 55

WELCOME MESSAGE.

Welcome to the vibrant city of Dubai!

It is with immense pleasure and anticipation that we extend our warmest greetings to each one of you where we embark on a collective journey towards achieving Excellence in Oncology Care (EIOC).

Over a decade, EIOC has transformed and aspired to stand as a neutral platform where all healthcare professionals come together to Access, Collaborate, and Educate for the betterment of patient care.

EIOC has been a beacon, bringing together some of the most exceptional minds in multidisciplinary Oncology Care and advancing oncology medical education in the UAE and beyond. EIOC 2026 is a testament to this legacy, made possible with the unwavering support of esteemed institutions and associations, including the **Dubai Health Authority (DHA),** and our valued collaborators, the **Arab Association of Urology (AAU), the Arab School of Urology (ASU), Emirates Oncology** and **Hematology Nursing Society, Emirates Society of Colon and Rectal Surgery, Foundation of Head & Neck Oncology, International Federation of Head and Neck Oncologic Societies and Tata Memorial Hospital.**. This meeting would also not have been possible without support from our industry partners and request you all to kindly take time to visit their booths and network.

In an era where data, research, and science are evolving at an unprecedented pace, we are thrilled to announce that **EIOC 2026** will be hosted at Intercontinental Hotel – Festival City in Dubai, with live, in-person sessions taking place on **13th and 14th November 2026.** Additionally, on the **15th of November, 2026,** we will be offering a virtual program, ensuring accessibility to a broader audience.

EIOC over the next 3 days promises to be a truly exceptional event, with lineup of global experts who will lead dedicated sessions on the most pressing topics in Oncology Care, ranging from Breast Cancer, Lung Cancer, Immuno-Oncology, GI Oncology, Molecular Tumour Boards, Oncology Nursing and many more.

The EIOC team eagerly anticipates your presence as we come together to advance medical education for all healthcare professionals at EIOC 2026. Your participation is integral to the success of this event, and we are confident that your insights and contributions will make a significant impact on the field of Oncology Care.
Once again, welcome to EIOC 2026, and we look forward to sharing this remarkable journey with you.

Regards,
On behalf of EIOC 2026 Leadership

EIOC LEADERSHIP.



Shaheenah Dawood
United Arab Emirates



Alexandra Economacos
United Arab Emirates



Archana Shetty
United Arab Emirates



Bhawna Sirohi
India



Jaikishan Mordani
United Arab Emirates



Khaled Al Qawasmeh
United Arab Emirates



Mona Tareen
United Arab Emirates



Nitesh Rohatgi
India



Pankaj Chaturvedi
India



Prabhash Kumar
India



Shailesh Shrikhande
India



Shona Nag
India



Sudeep Gupta
India



Tobias Arkenau
United Kingdom



Wafaa Ayesh
United Arab Emirates



Yasser Farahat
United Arab Emirates



Yogesh More
United Arab Emirates

APMEA ONCOLOGY
OLECULAR™
TUMOR BOARD

CONNECTING ONCOLOGY EXPERTS **GLOBALLY**

An Online Platform Powering Excellence in Oncology Care

A COMPLETE ONCOLOGY HUB

- Case-Based Learning
- Expert Faculty Network
- Live & Virtual Events
- On-Demand Educational Resources
- Multidisciplinary Collaboration
- Regional & Global Networking
- Peer-to-Peer Knowledge Exchange
- Patient-Focused Initiatives

WHAT DO WE ENABLE

Cross-Border Collaboration

Connecting regional and international oncology experts through peer-to-peer, case-based discussions.

Expert-Led Education

Interactive case discussions, webinars, and multi-platform learning experiences available live and on demand.

Scientific Independence

Multi-stakeholder collaboration guided by science, real-world data, and educational excellence.

Patient Advocacy

Empowering patients and caregivers through shared experiences, survivorship insights, and meaningful dialogue.

Website

YouTube

Visit **apmeaoncology.com** & our **YouTube channel** to discover our programs, educational resources, and upcoming events.

OUR INITIATIVES

Journal club™

In ..... Conversation Series™

ONCO DISCUSSIONS

FIRESIDE Chat

Patient Advocacy Forum™

Workshop™


OUR IMPACT

Countries Streamed To
60+

HCP Viewership Over the Years
10,000+

International Faculty Hosted
100+

On-demand Educational Sessions & Webinars
150+



REGIONAL PRESENCE

Middle East
United Arab Emirates, Saudi Arabia, Oman, Qatar, Lebanon, Turkey, Kuwait, Egypt

Asia-Pacific
Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Sri Lanka, Nepal, Hong Kong, India, Pakistan, Bangladesh

Africa
Egypt and expanding partnerships across the region

INTERESTED IN SPONSORING A WEBINAR?

Mr. Arjun Meethal
+971 56 603 3497 arjun.meethal@index.ae

Webinars Powered By

INDEX CONFERENCES & EXHIBITIONS

MEET THE

FACULTY

INTERNATIONAL.REGIONAL.LOCAL

EIOC2026

cancercongress.ae

INTERNATIONAL FACULTY.



Angélica Rodrigues
Federal University of Minas Gerais
Brazil



Axel Grothey
West Cancer Center and Research Institute
USA



Claude Chidiac
Homerton Healthcare NHS Foundation Trust
UK



David Ilson
Memorial Sloan Kettering Cancer Center
USA



Devan Moodley
Wits Donald Gordon Medical Centre
South Africa



Elizabeth Smyth
Oxford University NHS Foundation Trust
UK



Emese Zsiros
Roswell Park Comprehensive Cancer Center
USA



Erica Mayer
Dana-Farber Cancer Institute
USA



Erin Buczek
University of Kansas Medical Center
USA



Filippo Pietrantonio
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Italy



Francois-Clement Bidard
Institut Curie & UVSQ/ Université Paris-Saclay
France



George Sledge
Caris Life Sciences
USA



Giuseppe Curigliano
Istituto Europeo di Oncologia and University of Milano
Italy



Javier Cortes
International Breast Cancer Center (IBCC), Barcelona
Spain



Jens Samol
Tan Tock Seng Hospital
Singapore



Joline Lim
Curie Oncology
Singapore

INTERNATIONAL FACULTY.



Lizza Hendriks
Maastricht University Medical Center
Netherlands



Mastura Yusof
PICASO Hospital
Malaysia



Peter Fasching
University Hospital Erlangen
Germany



Pongwut Danchaivijitr
Siriraj Hospital
Thailand



Tobias Arkenau
Ellipses Pharma
UK



Consistent results across a broad range of HR+/HER2-eligible⁺patients with statistically significant improvements in iDFS (eBC), PFS and OS (aBC).*1-5

⁺ Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence, advanced or metastatic breast cancer.
* vs AI in the NATALEE study and ET in the MONALEESA studies.[1]

1. Hortobagyi GN, et al. N Engl J Med. 2022;386(10):942–950.
2. Lu Y-S, et al. Clin Cancer Res. 2022;28:851–859.
3. Slamon DJ, et al. Ann Oncol. 2021;32(8):1015–1024.
4. D. Slamon, et al. N Engl J Med 2024;390:1080-91
5. KISQALI (Ribociclib) Prescribing Information
eBC: Early Breast Cancer, aBC: Advanced Breast Cancer

Fictional healthcare professional and patient

Scan here for National Succinct Statement (NSS)

NOVARTIS

Novartis Middle East FZE
P.O. Box 23510, Dubai
United Arab Emirates.
Tel: +971 4 4357002
www.novartis.com

KISQALI® ribociclib
Powerful consistency

FA-11507412

REGIONAL FACULTY.



Abdul Rehman Zar
Hamad Medical Corporation
Qatar



Abhishek Vaidya
National Cancer Institute, Nagpur
India



Ahmad Al Ghoche
Sultan Qaboos Comprehensive Cancer Care and Research Center
Oman



Ahmed Saadeddin
Al Habib Medical Group
KSA



Ajit Venniyoor
National Oncology Center, The Royal Hospital
Oman



Akhil Kapoor
Tata Memorial Hospital
India



Alaaeldin Shablak
National Center for Cancer Care and Research
Qatar



Amir Abdelazim
Kuwait Cancer Control Center
Kuwait



Ammar Madani
National Center for Cancer Care and Research
Qatar



Anuj Gupta
Tata Memorial Hospital
India



Apurva Garg
Care Cancer Institute Care - CHL Hospital
India



Aref Zribi
Sultan Qaboos Comprehensive Cancer Care and Research Center
Oman



Aseem Mishra
Mahamana Pandit Madan Mohan Malviya Cancer Centre & Tata Memorial Centre
India



B.K.Mishra
HBCH & MPMMCC, Tata Memorial Centre
India



Bhawna Sirohi
BALCO Medical Centre
India



Cinjini Das
Manipal Hospitals E.M. Bypass
India

REGIONAL FACULTY.



Deepa Nair
Tata Memorial Centre
India



Dorria Salem
Cairo University
Egypt



Guru Charan Sahu
Tata Memorial Centre
India



Hamdy Abdul Azim
Cairo University
Egypt



Hazem Assi
American University of Beirut
Lebanon



Hind El Malik
Hamad Medical Corporation
Qatar



Hitesh Singhavi
KIMS Hospitals, Thane
India



Ikram Burney
Sultan Qaboos Comprehensive Cancer Care & Research Center, University Medical City
Oman



Kakil Rasul
National Center for Cancer Care and Research
Qatar



Kinshuk Chatterjee
Manipal Hospitals Kolkata
India



Kumar Prabhash
Tata Memorial Hospital
India



Manish Mair
University Hospital of Leicester NHS Trust
India



Mohamed Ashour
Kuwait Cancer Control Center
Kuwait



Mohsen Mokhtar
Cairo University
Egypt



Neelesh Tiwari
Chirayu Cancer Hospital, Bhopal
India



Nirav Trivedi
Shanku's Medicity Hospital
India

REGIONAL FACULTY.



Nita Nair
Apollo Cancer Centre
India



Nitesh Rohatgi
Fortis Memorial Research Institute
India



Nuha Khoumais
Alrajhi Medicine
KSA



Omshree Shetty
Tata Memorial Hospital
India



Ozge Keskin
King Hamad University Hospital
Bahrain



Pankaj Chaturvedi
Tata Memorial Centre
India



Pattatheyil Arun
Tata Memorial Centre
India



Prabhat Malik
All India Institute of Medical Sciences, New Delhi
India



Rajiv Kaushal
Tata Memorial Hospital
India



Rajjyoti Das
Dr Bhubaneswar Borooah Cancer Institute
India



S Kannan
Apollo Cancer Centre
India



Sarbani Ghosh Laskar
Tata Memorial Hospital
India



Satish Sharma
Bhagwan Mahavir Manipal Superspecialty Hospital
India



Sayan Das
Manipal Hospital
India



Sewanti Limaye
Sir H. N. Reliance Foundation Hospital, Mumbai
India



Shailesh Shrikhande
Tata Cancer Care Foundation, Gleneagles Hospital
India

REGIONAL FACULTY.



Shona Nag
Lokmanya Hospitals
India



Shwetabh Sinha
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre
India



Sinem Akbas
Bahrain Oncology Center
Bahrain



Sourav Datta
Manipal Hospital, Kolkata
India



Sudeep Das
Manipal Hospitals E.M. Bypass
India



Suhaila Al Farsi
Sultan Qaboos Comprehensive Cancer Care & Research Center
Oman



Sulaiman Al Saadi
Sultan Qaboos Comprehensive Cancer Care and Research Center
Oman



Suman Mallik
Narayana Health
India



Swagnik Chakrabarti
Chandan Hospital in Gomtinagar
India



Tala Al-Dabbous
Kuwait Association for the Care of Children in Hospital and Bayt Abdullah Children's Hospice
Kuwait



Tara Chand Gupta
Bhagwan Mahaveer Hospital & Research Center, Jaipur
India



Tarkan Yetişyiğit
Bahrain Oncology Center, Royal Medical Services
Bahrain



Ullas Batra
Rajiv Gandhi Cancer Institute
India



Vanita Noronha
Tata Memorial Hospital
India



Vijay Maruti Patil
SunAct Cancer Institute Pvt. Ltd.
India



Vivekananda Singh
Medanta Lucknow
India

MEDICLINIC ميديكلينيك

COMPREHENSIVE CANCER SERVICES

Selected Mediclinic hospitals in Dubai and Abu Dhabi provide comprehensive cancer care utilising the advanced diagnostic approaches, as well as medical and surgical treatments, all tailored to each patient's individual needs.

Our multidisciplinary teams, with representation from a wide range of specialists, follow internationally recognised guidelines to provide the best possible outcomes throughout the treatment process.

Download the Mediclinic App or call:
Dubai facilities - **800 1999** | Abu Dhabi and Al Ain facilities - **800 2000**



LOCAL FACULTY.



Abdul Rahman El Kinge
NMC Royal Hospital - Sharjah
UAE



Ahmad Al Rifai
Sheikh Shakhbout Medical City
UAE



Ahmad Ali Basha
Saudi German Hospital - Dubai
UAE



Ahmad Raza
Cleveland Clinic Abu Dhabi
UAE



Alaa Al Abbadi
Cleveland Clinic Abu Dhabi
UAE



Aladdin Maaraoui
Gulf International Cancer Centre
UAE



Alexandra Economacos
Mediclinic City Hospital
UAE



Ali Chamseddine
Al Zahra Hospital - Dubai
UAE



Aly Abdel Razek
Gulf International Cancer Centre
UAE



Amal Al Haddad
Shaikh Shakhbout Medical City
UAE



Amer Mousa
Clemenceau Medical Center
UAE



Archana Shetty
Mediclinic Parkview Hospital, Dubai
UAE



Aref Chehal
Sheikh Shakhbout Medical City
UAE



Arun Karanwal
Prime Hospital
UAE



Ashok Bohra
Mediclinic Middle East
UAE



Ayman Al Harakeh
Mediclinic Middle East
UAE

LOCAL FACULTY.



Balaji Balasubramanian
NMC Specialty Hospital
UAE



Basel Al Haj Ali
Sheikh Khalifa Specialty Hospital
UAE



Batool Aboud
Saudi German Hospital - Dubai
UAE



Bharadwaj Ponnada
Zulekha Hospital - Dubai
UAE



Cherian Thampy
NMC Hospital
UAE



Dalia ElShorbagy
Dubai Hospital
UAE



Deborah Mukherji
Clemenceau Medical Center
UAE



Dima Jabbar
Cleveland Clinic Abu Dhabi
UAE



Dorai Ramanathan
Al Zahra Hospital
UAE



Doreen Odjidja
Amana Healthcare
UAE



Fadi Alnehlaoui
Sama Medical Centet, Medcare Hospitals
UAE



Falah Al Khatib
Advanced Care Oncology Center
UAE



Farah Farroukh
Cleveland Clinic Abu Dhabi
UAE



Faraz Khan
American Hospital
UAE



Fathi Azribi
American Hospital Dubai
UAE



Fiji Antony
NMC Specialty Hospital
UAE

LOCAL FACULTY.



Gonçalo Ferreira
Burjeel Medical City
UAE



Hala Abd El Latif
Mediclinic Airport Road Hospital
UAE



Hassan Ghazal
Kings College Hospital Dubai
UAE



Hassan Shahryar
American Hospital Dubai
UAE



Hemant Vadeyar
Mediclinic Middle East
UAE



Hiran Ravindran
Burjeel Hospital
UAE



Husam Marashi
Tawam Hospital
UAE



Ibrahim Abu Gheida
Burjeel Medical City
UAE



Jaikishan Mordani
Mediclinic Middle East
UAE



Jawaher Ansari
Tawam Hospital
UAE



John Ionescu
German Integrative Medical Center, Tadawi Speciality Hospital
UAE



Kaltar Das
Dubai Health and Academic Corporation
UAE



Karim Medhat Elmasry
Mediclinic Middle East
UAE



Khaled Al-Qawasmeh
Tawam Hospital
UAE



Khaled Kouteich
Al Zahra Hospital Dubai
UAE



Kinda Douaidari
Mediclinic Middle East
UAE

LOCAL FACULTY.



Kristal Foster
Music Therapist
UAE



Maan Hachmi
Dubai Hospital
UAE



Magda Snowden
Thriving Together
UAE



Mahdi Shoukakani
Cleveland Clinic Abu Dhabi
UAE



Manuelita Mazza
Cleveland Clinic Abu Dhabi
UAE



Mariam AlHilli
Cleveland Clinic Abu Dhabi
UAE



Maroun El Khoury
American Hospital Dubai
UAE



Mazin Aljabiri
Mediclinic Parkview Hospital
UAE



Mazin Al-Janabi
Mediclinic Middle East
UAE



Medhat Faris
Advance Care Oncology Centre
UAE



Mehdi Afrit
Burjeel Hospital Sharjah
UAE



Melanie Schlatter
American Hospital
UAE



Mohammed Al Ali
Sheikh Shakhbout Medical City
UAE



Mohanad Diab
Mediclinic Abu Dhabi
UAE



Mona Tareen
Cleveland Clinic Abu Dhabi
UAE



Mourad Salam
Gulf International Cancer Center
UAE

LOCAL FACULTY.



Muhammad Elmussareh
American Hospital Dubai
UAE



Nihal Yildirim
Mediclinic Parkview Hospital
UAE



Nouraddine Alhasan
Tawam Hospital
UAE



Noureen Saber
Dubai Health
UAE



Omer Al Derwish
Fakeeh University Hospital
UAE



Patrizia Porcu
Mediclinic City Hospital
UAE



Puja Gaur Khaitan
Sheikh Shakhbout Medical City
UAE



Rakesh Rai
King's College Hospital Dubai
UAE



Ramanujam Singarachari
Mediclinic Airport Road
UAE



Rana Irfan Mahmood
Mediclinic City Hospital
UAE



Rehaan Nensey
Mediclinic Middle East
UAE



Reham Omar
NMC Healthcare
UAE



Rham Zaki Ahmed
Zulekha Hospital, Sharjah
UAE



Roger Gerjy
Mediclinic Middle East
UAE



Rosemary Wasti
Cleveland Clinic Abu Dhabi
UAE



Roshan Koshy Jacob
NMC Healthcare
UAE

LOCAL FACULTY.



Salman Sray Aldeen
Sheikh Khalifa Specialty Hospital
UAE



Salsabil Ibrahim
SKSH
UAE



Samer Elkaissi
Endocrinology, MSI, Cleveland Clinic, Abu Dhabi
UAE



Sara Al Bastaki
Mediclinic City Hospital
UAE



Sara Jimenez
Cleveland Clinic Abu Dhabi Diagnostics Institute
UAE



Sasha McLeod
Creative Health Therapies FZC
UAE



Sathis Mogan
Mediclinic Parkview Hospital
UAE



Sebastian Rees
Cleveland Clinic Abu Dhabi
UAE



Shaik Irfan Basha
Burjeel Medical City
UAE



Shilpa Kudekar
Farasha Wellbeing
UAE



Shyla Sajan
Dubai Health Authority
UAE



Sondos Yadak
Dubai Health Authority
UAE



Sonia Otsmane
Burjeel Medical City
UAE



Sukrith Shetty
NMC Healthcare
UAE



Susheel Kumar
Dubai Hospital
UAE



Syed Monawer Karim
King's College Hospital London - Dubai
UAE

LOCAL FACULTY.



Tarek Alkhouri
Medcare Hospital
UAE



Tarek Dufan
American Hospital
UAE



Thamir Alkasab
Al Zahra Hospital
UAE



Thanda Lucy Ann Joshua
Burjeel Hospital
UAE



Urfan Ulhaq
Burjeel Hospital
UAE



Wafaa Ayesh
Tadawi General Hospital
UAE



Wisam Ismail
Mediclinic Parkview Hospital, Dubai
UAE



Yasser Farahat
Sheikh Khalifa General Hospital
UAE



Yogesh More
Burjeel Medical City
UAE



Yoginee Sonawane
Burjeel Medical City
UAE



Yousra Izzuddeen KN
Burjeel Medical City
UAE



Zakir Mohamed
NMC Royal Hospital
UAE

Program at a Glance.

DAY ONE | FRIDAY | 13 NOVEMBER, 2026 | IN-PERSON

	AL RAS 2	AL RAS 3	AL AMWAJ	AL NOOR
MORNING SESSIONS	GI Cancer	Head & Neck Cancer	Oncology Nutrition	Patient Advocacy Forum

Prayer Break and Lunch Break

	AL RAS 2	AL RAS 3	AL AMWAJ	AL NOOR
AFTERNOON SESSIONS	Gynae-Oncology and Novel Therapeutics	Head & Neck Cancer	Breast Imaging / Surgical	Young Leaders in Oncology

Takeaways and End of Day One

DAY TWO | SATURDAY | 14 NOVEMBER, 2026 | IN-PERSON

	AL RAS 2	AL RAS 3	AL AMWAJ
MORNING SESSIONS	Lung Cancer	Breast Cancer	Uro-Oncology

Lunch Break

	AL RAS 2	AL RAS 3	AL AMWAJ	AL NOOR
AFTERNOON SESSIONS	Lung Cancer	Breast Cancer	Oncology Nursing	Palliative & Supportive Care

Abstract Winner Announcement and Takeaways of Day Two

DAY THREE | SUNDAY | 15 NOVEMBER, 2026 | VIRTUAL

	VIRTUAL HALL | NO EXHIBITION
MORNING SESSION	APMEA Molecular Tumor Board

Closing Remarks

INDEX PCO is dedicated to organising Professional Congresses with a focus in the Healthcare & Life Sciences Sector.



CONTACT US FOR ALL YOUR CONFERENCE REQUIREMENTS:

Email: indexpco@index.ae

HQ Dubai Office:

INDEX Holding Headquarters,
Road D-62, Opposite Nad Al Hamar,
P.O. Box 13636, Dubai – UAE

Singapore Office:

1 Raffles Boulevard – Suntec City,
Level 3 Venue Management Office,
Singapore 039593

CONFERENCE SECRETARIAT

INDEX Conferences & Exhibitions Organization Est.
P.O. Box 13636, Road # D-62, Opposite Nad Al Hamar, Dubai, United Arab Emirates
Tel: +971 4 520 8888, Fax: +971 4 338 4193, Email: indexpco@index.ae, Website: index.ae

DAY ONE

13 NOVEMBER 2026

IN-PERSON.DUBAI

EIOC2026
cancercongress.ae

GI Cancer Session.

DAY ONE - AGENDA

SUPPORTED BY

EMIRATES SOCIETY OF COLORECTAL SURGERY

13 November 2026 (Friday) | **08:30 – 12:45** Hrs GST | **In Person** | **Al Ras 2**

SESSION 1: Plenary and Lower GI Tract

Chairpersons: **Sara Al Bastaki, UAE | Ali Chamseddine, UAE | Rakesh Rai, UAE**

08:30 – 08:40	**Opening Remarks**
08:40 – 09:05	Year in Review: What Worked and What Didn't! **David Ilson, USA**
09:05 – 09:25	Evolving Management of Rectal Cancer: From TNT to Watch and Wait **Filippo Pietrantonio, Italy**
09:25 – 10:10	Panel Discussion: Challenging Cases in Lower GI Tumors Moderators: **Bhawna Sirohi, India | Sewanti Limaye, India** Panel: **David Ilson, USA | Kakil Rasul, Qatar | Zakir Mohamed, UAE** **Arun Karanwal, UAE | Tarek Dufan, UAE | Alaaeldin Shablak, Qatar** **Deborah Mukherji, UAE | Roger Gerjy, UAE**
10:10 – 10:25	Redefining First Line Hepatocellular Carcinoma, The Power of Dual Immunotherapy - ***Satellite Symposium by BMS*** **Aref Chehal, UAE**
10:25 – 10:45	**Coffee Break**

SESSION 2: Upper GI Tract

Chairpersons: **Ahmad Al Ghoche, Oman | Alaaeldin Shablak, Qatar**

10:45 – 11:05	Panel Discussion: Challenging Cases in Upper GI Tumors Moderators: **Bhawna Sirohi, India | Alaaeldin Shablak, Qatar** Panel: **Tarkan Yetişyiğit, Bahrain | Ajit Venniyoor, Oman | Elizabeth Smyth, UK** **Hemant Vadeyar, UAE | Ashok Bohra, UAE | David Ilson, USA** **Syed Monawer Karim, UAE | Ramanujam Singarachari, UAE**
11:05 – 11:20	Unlocking CLDN18.2: Redefining First-Line Treatment with Zolbetuximab - ***Satellite Symposium by Astellas*** Chairperson: **Shaheenah Dawood, UAE** Speaker: **Husam Marashi, UAE**

GI Cancer Session.

DAY ONE - AGENDA

11:20 – 11:35	Integrating Immunotherapy in Advanced Upper GI Tumors: The Challenges, The Pitfalls and the Success **Elizabeth Smyth, UK**
11:35 – 11:55	Setting a New Benchmark in Resectable GC: Perioperative Immunotherapy Efficacy and Safety Data - ***Satellite Symposium by AstraZeneca*** **Shaheenah Dawood, UAE**
11:55 – 12:10	Transforming the Management of Upper GI Cancers with Immunotherapy - ***Satellite Symposium by BMS*** **Tarkan Yetişyiğit, Bahrain**
12:10 – 12:45	Panel Discussion: Challenging Cases in GI Surgery Moderator: **Shailesh Shrikhande, India** Panel: **Ahmad Al Ghoche, Oman | Sara Al Bastaki, UAE | David Ilson, USA Sathis Mogan, UAE | Batool Aboud, UAE | Mazin Aljabiri, UAE Rakesh Rai, UAE | Urfan Ulhaq, UAE | Ayman Al Harakeh, UAE Rehaan Nensey, UAE**
12:45	**Closing Remarks & Lunch Break**

Gynae-Oncology & Novel Therapeutics Session.

DAY ONE - AGENDA

13 November 2026 (Friday)	**13:30 – 16:30** Hrs GST	**In Person**	**Al Ras 2**

SESSION 1

Chairpersons: **Sulaiman Al Saadi, Oman | Noureen Saber, UAE**

13:30 – 13:35	**Opening Remarks**
13:35 – 13:55	Management of Vasomotor Symptoms in Post-Menopausal Women **Mariam AlHilli, UAE**
13:55 – 14:15	Evolving Treatment Paradigm in the Landscape of Platinum Resistant Ovarian Cancer - ***Satellite Symposium MSD*** **Emese Zsiros, USA**
14:15 – 14:35	Panel Discussion: Challenging Cases in Ovarian Cancer Moderator: **Shona Nag, India** Panel: **Ikram Burney, Oman | Karim Elmasry, UAE | Emese Zsiros, USA Mariam AlHilli, UAE | Sinem Akbas, Bahrain | Mohanad Diab, UAE Kakil Rasul, Qatar | Faraz Khan, UAE | Hassan Ghazal, UAE**

SESSION 2

Chairpersons: **Ikram Burney, Oman | Ahmad Ali Basha, UAE**

14:35 – 14:55	Emerging Landscape in LA Cervical Cancer Management - ***Satellite Symposium by MSD*** **Angelica Rodrigues, Brazil**
14:55 – 15:15	Panel Discussion: Challenging Cases in Cervical Cancer Moderator: **Mohsen Mokhtar, Egypt** Panel: **Angelica Rodrigues, Brazil | Mariam AlHilli, UAE | Karim Elmasry, UAE Khaled Kouteich, UAE | Mohamed Ashour, Kuwait Dorai Ramanathan, UAE | Shona Nag, India**
15:15 – 15:35	Pivotal Role of Checkpoint Blockade in Management of Endometrial Carcinoma - ***Satellite Symposium MSD*** **Mohsen Mokhtar, Egypt**

Gynae-Oncology & Novel Therapeutics Session.

DAY ONE - AGENDA

15:35 – 15:55	Panel Discussion: Challenging Cases in Endometrial Cancer Moderator: **Tarkan Yetisyegi, Bahrain | Ramanujam Singarachari, UAE** Panel: **Ajit Venniyoor, Oman | Sukrith Shetty, UAE | Basel Al Haj Ali, UAE Mariam AlHilli, UAE | Karim Elmasry, UAE | Mohsen Mokhtar, Egypt Dalia Elshorbagy, UAE**
15:55 – 16:10	Transforming Therapeutic Strategies in Platinum Resistant Ovarian Cancer - ***Satellite Symposium by Abbvie*** **Ikram Burney, Oman**
16:10 – 16:25	Novel Targets and Therapeutics in Gynecological Cancer **Angelica Rodrigues, Brazil**
16:25 – 16:30	**Closing Remarks | End of Session**

Head&Neck Oncology Masterclass.

DAY ONE - AGENDA

SUPPORTED BY

13 November 2026 (Friday) | **08:30 – 17:15** Hrs GST | **In Person** | **HALL**

08:30 – 08:40	**Welcome Address** **Pankaj Chaturvedi, India**
SESSION 1 - Short Video Session Chairperson: **Rajjyoti Das, India | Aseem Mishra, India**	
08:40 - 08:50	Endoscopic Cranio-Facial Resection **Neelesh Tiwari, India**
08:50 - 09:00	Infratemporal Fossa Clearance **Nirav Trivedi, India**
09:00 - 09:10	Supracricoid Laryngectomy **Apurva Garg, India**
09:10 - 09:30	**Q & A**
SESSION 2 Chairperson: **Yoginee Sonawane, UAE | Iyad Hamadi, UAE**	
09:30 – 10:00	Thyroid Keynote: ATA 2025 Guidelines Update **Erin Buczec, USA**
10:00 – 10:45	**Panel Discussion** on Thyroid and Parathyroid Malignancy Moderator: **Yogesh More, UAE** Panelists: **Balaji Balasubramanian, UAE | Erin Buczek USA** **Samer Elkaisisi, UAE | Gonçalo Ferreira, UAE** **Mahdi Skoukani, UAE | Nouraddine Alhasan, UAE** **Hiran Ravindran, UAE**
10:45 – 11:00	**Coffee Break and Poster Viewing**

Head&Neck Oncology Masterclass.

DAY ONE - AGENDA

SESSION 3

Chairperson: **Deepa Nair, India | Ibrahim Abu Gheida, UAE**

11:00 – 11:30	**Debate 1:** Peri-Operative Immunotherapy is Ready for Prime Time Standard of Care in All Resectable Oral Cancers Moderator: **Pankaj Chaturvedi, India | Abdul Rehman Zar, Qatar** Proposition: **Vijay Patil, India** Opposition: **Pattatheyil Arun, India**
11:30 – 12:15	**IFHNOS Panel Discussion** – Controversies in Management of Laryngo-Pharyngeal Cancer Moderator: **Nirav Trivedi, India** Panelists: **Pattatheyil Arun, India | S Kannan, India | Suman Mallik, India** **Satish Sharma, India | Sarbani Ghosh Laskar, India** **Kinshuk Chatterjee, India | Yousra Izzuddeen, UAE** **Mohammed Al Ali, UAE | Abdul Rehman Zar, Qatar** **Aseem Mishra, India**
12:15 - 14:00	**Friday Prayer & Lunch Break**

SESSION 4 - Multidisciplinary Management of Head & Neck Cancers

Chairpersons: **Pattatheyil Arun, India | Nirav Trivedi, India**

14:00 – 14:15	Induction Chemotherapy to Perioperative Immunotherapy – Evolving Role of Medical Oncologists in the Management of Oral Cancer **Kumar Prabhash, India**
14:15 – 14:30	De-escalation of Surgery in the Management of Differentiated Thyroid Cancer **Abhishek Vaidya, India**
14:30 – 14:45	Advantage of Proton Therapy Over IGRT In Head and Neck Cancer **Sarbani Ghosh Laskar, India**
14:45 – 15:00	Reconstruction Strategies Including Implants **Manish Mair, India**
15:00 – 15:45	**FHNO Panel Discussion** - Controversies in the Management of Oral Cancer Moderator: **Swagnik Chakrabarty, India** Panelists: **Vivekananda Singh, India | Sayan Das, India | Hitesh Singhavi, India** **Cinjini Das, India | Guru Charan Sahu, India | Shaik Irfan Basha, UAE** **Sudeep Das, India | Ammar Madani, Qatar**

Head&Neck Oncology Masterclass.

DAY ONE - AGENDA

15:45 – 16:00	**Coffee Break and Poster Viewing**
16:00 – 16:30	**Debate 2:** Organ Preservation Non-Surgical Strategies are the Treatment of Choice for All T3 Laryngeal / Hypopharyngeal Cancers Moderator: **Sarbani Ghosh Laskar, India | Ammar Madani, Qatar** Proposition: **Shwetabh Sinha, India** Opposition: **Sourav Datta, India**
16:30 – 17:15	**Panel Discussion** on PNS and Salivary Gland Tumors Moderator: **Deepa Nair, India** Panelists: **Nirav Trivedi, India | Rajjyoti Das, India | Aseem Mishra, India Shwetabh Sinha, India | Sudeep Das, India | S Kannan, India Hiran Ravindran, UAE**
17:15	**Concluding Remarks** **Pankaj Chaturvedi, India**

Oncology Nutrition Session.

DAY ONE - AGENDA

13 November 2026 (Friday)	09:00 – 11:40 Hrs GST	In Person	Al Amwaj

09:00 – 09:05	**Opening & Welcome** Introduction to the Oncology Nutrition Track **Wafaa Ayesh, UAE**

From Diagnosis to Survivorship: Precision Nutrition in Cancer Care
Chairperson: **Wafaa Ayesh, UAE**

09:05 – 09:35	**Weight Loss Without Wasting** GLP-1 Therapies in Oncology **Abdul Rahman El Kinge, UAE**
09:35 - 10:05	**Personalized Onco-Nutrition** Related to the Tumor Metabolic Markers **John Ionescu, UAE**
10:05 – 10:35	**The First 30 Days Matter** Early Nutrition Screening, Assessment & Risk Stratification in Cancer **Wafaa Ayesh, UAE**
10:35 – 11:05	**Feed the Patient, Not the Tumor** Evidence-Based Nutrition Therapy During Cancer Treatment **Hassan Ghazal, UAE**
11:05 – 11:25	**When Weight Loss Is More Than Weight Loss** Cancer Cachexia, Sarcopenia & Multimodal Nutrition **Fiji Antony, UAE**
11:25 – 11:40	**Interactive Panel Discussion & Q&A** From Guidelines to Practice: Challenging Cases in Oncology Nutrition **All Faculty Members**
11:40	**Closing & Key Take-Home Messages**

Breast Imaging / Surgical Session.

DAY ONE - AGENDA

13 November 2026 (Friday)	**14:00 – 17:00** Hrs GST	**In Person**	**Al Amwaj**

SESSION 1 Chairperson: **Alexandra Economacos, UAE**	
14:00 – 14:10	**Opening Remarks**
14:10 – 14:25	De-escalation of Breast Cancer Surgery in Egypt: the Radiologist Role **Dorria Salem, Egypt**
14:25 – 14:45	De-escalation of Breast Cancer Surgery in KSA: the Radiologist Role **Nuha Khoumais, KSA**
14:45 – 15:05	BISUCO Trial and Literature Review on Vacuum Excision in Breast Cancer **Sara Jimenez, UAE**
15:05 – 15:25	Cryoablation: Literature Review and the UAE Experience **Maan Hachmi, UAE**
15:35 – 15:45	**Panel Discussion**
15:45 – 16:00	**Coffee Break**
16:00 – 16:30	Single Port Robotic Breast Surgery **Wisam Ismail, UAE**
16:30 – 17:00	**Case Discussion:** Tumor Cell Seeding Associated with Needle Biopsy in Patients with Breast Cancer Moderator: **Wisam Ismail, UAE** Panelists: **Kinda Douaidari, UAE | Aly Abdel Razek, UAE | Kakil Rasul, Qatar Hala Abdellatif, UAE | Jaikishan Mordani, UAE | Patrizia Porcu, UAE Fadi Alnehlaoui, UAE**
17:00	**Q&A and Closing Remarks**

Young Leaders in Oncology Session.

DAY ONE - AGENDA

13 November 2026 (Friday)	14:00 – 16:10 Hrs GST	In Person	Al Noor

Young Leaders in Oncology Session

Judges: **Bhawna Sirohi, India | Ramanujam Singarachari, UAE | Shailesh Shrikhande, India**

14:00 – 14:10	**Opening Remarks**
14:10 – 14:20	Assessing Cancer-Related Fatigue and Functional Performance among Adults Living with Cancer in Palestine: A Multicentre Cross-Sectional Survey **Bilal Awad, Palestine**
14:20 - 14:30	Assessment of Nutritional Challenges and Educational Needs Among Cancer Patients Receiving Chemotherapy in Al-Najaf, Iraq **Fatimah Al-Shabbani, Iraq**
14:30 - 14:40	Chronic Bowel Symptoms Following Pelvic Radiotherapy in Cervical Cancer: A Systematic Review of Patient-Reported Outcomes **Maya El Toukhy, UK**
14:40 - 14:50	Beyond BRCA1/2: Germline Pathogenic Variants in North Indian Breast and Ovarian Cancer Patients **Archi Rungta, India**
14:50 - 15:00	Selective Testing Misses Half of The Germline Pathogenic Variant Carriers in Epithelial Ovarian Cancer: Evidence from a North Indian Cohort **Anjana Anoop, India**
15:00 - 15:10	Real-World Impact of Mismatch Repair Immunohistochemistry in Solid Tumours: An Indian Cohort Study **Ashwin Philips, India**
15:10 - 15:20	Expression of p63, CD10, And Ki-67 in Giant Cell Tumour of Bone: A Diagnostic Immunohistochemical Study **Eman Ibrahim, UAE**
15:20 - 15:30	Development of an Ultrasensitive Liquid (Saliva) Biopsy Investigative Diagnostic Devices for Early Detection of Oral Cancer Using Multiplex Biomarker Profiling. **Shaista Suhail, India**

Young Leaders in Oncology Session.

DAY ONE - AGENDA

15:30 - 15:40	Dysregulation of Cell Death Signaling Across the Glioblastoma Tumor Microenvironment **Solima Sabeel, UAE**
15:40 - 15:50	Horizon Spectra Module: Accelerating Diagnostic Resolution of Somatic Variants and Tumor Profiling **Marese Grehan, Canada**
15:50 - 16:00	Safety and Efficacy of Sunvozertinib Monotherapy in Egfr Exon 20 Insertion-Mutated Advanced Non-Small Cell Lung Cancer: A Systematic Review and Single-Arm Meta-Analysis **Ruben Simon Roy, UAE**
16:00 - 16:10	The effects of Lokomat training (robotic-assisted exoskeleton) on balance and muscle activity in oncology complicated neurological conditions (A retrospective study). **Mahmood Alhinaai, Oman**
16:10	**Closing Remarks**

In HR+, HER2- EBC

Overall survival is just one endpoint

For her, it could be the one that matters most.



Scan the QR code for Abbreviated Prescribing Information

Verzenio® abemaciclib

A Lilly Medicine

© 2026 Eli Lilly and Company. All Rights Reserved.
Lilly and Verzenio® are registered trademarks of Eli Lilly and Company.

For adverse events and safety reporting, please send an email: PV-MEA@lilly.com

For product complaints, please send an email: Ibmail_pc_mena@lilly.com

For further information about Lilly and Lilly products please contact us at the below address:
UAE: The Offices, One Za'abeel, Za'abeel Palace St, Za'abeel 1, Offices 701–705, Tower A,
P.O. Box 2039, Dubai, UAE, Tel.: (+971 4) 453 7800, Fax: (+971 4) 436 2399

Lilly
A MEDICINE COMPANY

CMAT-67560

RETHINK RISK.
RETHINK PROTECTION.



Scan the QR code for Abbreviated Prescribing Information

Verzenio® abemaciclib

A Lilly Medicine

© 2026 Eli Lilly and Company. All Rights Reserved.
Lilly and Verzenio® are registered trademarks of Eli Lilly and Company.

For adverse events and safety reporting, please send an email: PV-MEA@lilly.com

For product complaints, please send an email: Ibmail_pc_mena@lilly.com

For further information about Lilly and Lilly products please contact us at the below address:
UAE: The Offices, One Za'abeel, Za'abeel Palace St, Za'abeel 1, Offices 701–705, Tower A,
P.O. Box 2039, Dubai, UAE, Tel.: (+971 4) 453 7800, Fax: (+971 4) 436 2399

Lilly
A MEDICINE COMPANY

CMAT-67560

DAY

TWO

14 NOVEMBER 2026

IN-PERSON.DUBAI

EIOC2026

cancercongress.ae

Breast Cancer Session.

DAY TWO - AGENDA

14 November 2026 (Saturday)	08:30 – 16:35 Hrs GST	In Person	Al Ras 3

08:25 – 08:30	**Opening Remarks** **Shaheenah Dawood, UAE**
Plenary Session Chairpersons: **Cherian Thampy, UAE | Aladdin Marraoui, UAE**	
08:30 – 08:50	A Year in Review: What Have We Learned? **Erica Mayer, USA**
08:50 – 09:10	Escalating and De-Escalating Surgery in Breast Cancer **Nita Nair, India**
SESSION 1: HR-Positive Breast Cancer Chairpersons: **Susheel Kumar, UAE | Ali Chamseddine, UAE | Tarek AlKhouri, UAE**	
09:10 – 09:30	SERENA 6: Precision Oncology Paving the Way! **Francois-Clement Bidard, France**
09:30 - 09:45	NATALEE at 6 Years: Redefining the Horizon - ***Satellite Symposium by Novartis*** **Maroun El Khoury, UAE**
09:45 – 10:00	New Targets in HR +Ve Breast Cancer: Where is the Future Headed **Peter Fasching, Germany**
10:00 – 10:15	How Much and How Long Do We Need Endocrine Therapy for EBC? **Hamdy Abdul Azim, Egypt**
10:15 – 10:45	Panel Discussion: Giredestrant and Oral SERDS in HR+ Treatment Paradigm - ***Supported by Roche*** Moderator: **Maroun El Khoury, UAE** Speaker: **Shaheenah Dawood, UAE** Panel: **Hala Abdellatif, UAE | Ramanujam Singarachari, UAE** **Sonia Otsmane, UAE | Jawaher Ansari, UAE**
10:45 – 11:00	**Coffee Break**

Breast Cancer Session.

DAY TWO - AGENDA

11:00 – 11:15	Clarity at Every Decision: The Evolving Role of Genomic Testing in Early Breast Cancer - ***Satellite Symposium by Newbridge*** **Dalia Elshorbagy, UAE**
11:15 – 11:45	Tumor Board: Challenging Cases in HR +Ve EBC **Moderator:** Mohsen Mokhtar, Egypt **Panel:** Javier Cortes, Spain| Tarkan Yetişyiğit, Bahrain | Mohanad Diab, UAE Husam Marashi, UAE | Ramanujam Singarachari, UAE Francois-Clement Bidard, France
11:45 – 12:05	Management of aBC Patients with AKTm in 2L Post CDK4/6i - ***Satellite Symposium by AZ*** **Javier Cortes, Spain**
12:05 – 12:30	Rethink Risk, Rethink Protection: Bringing the Evidence into Everyday Practice in Early HR+/HER2- Breast Cancer - ***Satellite Symposium by Lilly*** **Jawaher Ansari, UAE**
12:30 – 12:45	Is There Still A Role for Cleopatra in HER2 Positive MBC? **Javier Cortes, Spain**
12:45 – 13:05	HER2+ in Focus: Connecting New ADC Evidence Across Patient Journey - ***Satellite Symposium by AZ*** **Shaheenah Dawood, UAE**
13:05 – 14:00	**Lunch Break**
SESSION 2: HER2 Positive Breast Cancer Chairperson: **Salsabil Ibrahim, UAE**	
14:00 – 14:15	Incorporating CTDNA Monitoring in Breast Cancer: Where are we in 2026? **Peter Fasching, Germany**
14:15 – 14:45	Tumor Board: Challenging Cases in HER2 Positive MBC **Moderator:** Shona Nag, India **Panel:** Francois-Clement Bidard, France | Suhaila Al Farsi, Oman Medhat Faris, UAE | Sinem Akbas, Bahrain | Peter Fasching, Germany
14:45 – 15:00	Optimizing Treatment Strategies in 2L + HR+ / HER2- Metastatic Breast Cancer: Understanding and Overcoming Resistance - ***Satellite Symposium by Menarini*** **Javier Cortes, Spain**

Breast Cancer Session.

DAY TWO - AGENDA

15:00 - 15:15	Ribociclib Transforming the Treatment Landscape of HR+/HER2- Metastatic Breast Cancer - ***Satellite Symposium by Novartis*** **Sonia Otsmane, UAE**
15:15 – 15:45	Tumor Board: Challenging Cases in HER2 Positive EBC? Moderator: **Nitesh Rohatgi, India** Panel: **Mehdi Afrit, UAE | Javier Cortes, Spain | Mohsen Mokhtar, Egypt** **Mourad Salam, UAE | Peter Fasching, Germany** **Maroun El Khoury, UAE | Ahmed Saadeddin, KSA**
15:45 – 16:05	From Data to Decisions: Applying the Evidence in HR+/HER2- Metastatic Breast Cancer - ***Satellite Symposium by Lilly*** **Fathi Azribi, UAE**
SESSION 3: Triple Negative Breast Cancer and Novel Therapeutics Chairpersons: **Falah Al Kathib, UAE| Nihal Yildirim, UAE | Suhaila Al Farsi, Oman**	
16:05 - 16:35	Tumor Board: Challenging Cases in TNBC (Early-Stage and Metastatic) Moderator: **Fathi Azribi, UAE** Panel: **Javier Cortes, Spain| Bharadwaj Ponnada, UAE | Ahmed Saadeddin, KSA** **Susheel Kumar, UAE | Rham Zaki Ahmed, UAE** **Manuelita Mazza, UAE | Dima Abdul Jabbar, UAE**
16:35	**Closing Remarks**

Lung Cancer Session.

DAY TWO - AGENDA

14 November 2026 (Saturday)	08:30 – 16:00 Hrs GST	In Person	Al Ras 2

SESSION 1

Chairpersons: **Reham Omar, UAE | Ahmad Raza, UAE | Mourad Salam, UAE**

08:30 - 08:35	**Opening Remarks**
08:35 - 08:55	Adjuvant Targeted Treatment in Lung Cancer – What Is New **Lizza Hendriks, Netherlands**
08:55 - 09:10	Digital Pathology in Lung Cancer – How to Apply in Clinic **Rajiv Kaushal, India**
09:10 - 09:30	Optimizing Care in Early and Locally Advanced NSCLC ***- Satellite Symposium by AstraZeneca*** **Cherian Thampy, UAE**
09:30 – 09:50	Expanding Role of Local Treatment in Advances Stage NSCLC **Puja Gaur Khaitan, UAE**
09:50 – 10:20	**Panel Discussion:** Case Based Discussion for Early-Stage Lung Cancer Moderator: **Vanita Noronha, India** Panellists: **Ammar Madani, Qatar | Tarkan Yetisyegi, Bahrain** **Akhil Kapoor, India | Ullas Batra, India | Puja Gaur Khaitan, UAE** **Lizza Hendriks, Netherlands | Anuj Gupta, India** **Mohsen Mokhtar, Egypt | Aref Chehal, UAE**
10:20 – 10:35	Long-term Clinical Outcome of Dual Immunotherapy in First Line Metastatic Non-small Cell Lung Cancer - ***Satellite Symposium by BMS*** **Dalia Elshorbagy, UAE**
10:35 – 10:45	**Q&A**
10:45 – 11:00	**Coffee Break**

SESSION 2

Chairpersons: **Thanda Lucy Ann Joshua, UAE | Rajiv Kaushal, India**

11:00 – 11:15	Locally Advanced NSCLC – State of Art **Lizza Hendriks, Netherlands**
11:15 – 11:30	The Strategic Impact of Cejemly (Sugemalimab) in Stage III & IV NSCLC - ***Satellite Symposium by Pharmalink*** **Shaheenah Dawood, UAE**

Lung Cancer Session.

DAY TWO - AGENDA

11:30 – 11:50	Mutation Negative Advanced Stage NSCLC – Have We Moved Beyond Checkpoint Inhibitors Only? **Sewanti Limaye, India**
11:50 – 12:05	Uncommon EGFR Mutation – How Do We Define Stratify the Treatment **Ullas Batra, India**
12:05 – 12:20	Her2 Mutation Positive NSCLC – Have We Expanded the Options **Hassan Shahryar, UAE**
12:20 – 12:50	**Panel Discussion:** Advanced Stage NSCLC – Case-Based Discussion EGFR And ALK Positive NSCLC Moderator: **Ullas Batra, India** Panellists: **Mohanad Diab, UAE | Roshan Koshy Jacob, UAE | B.K. Mishra, India Sewanti Limaye, India | Kumar Prabhash, India | Tara Chand Gupta, India Reham Omar, UAE**
12:50 – 13:00	**Q&A**
13:00 – 14:00	**Lunch Break**
SESSION 3 Chairpersons: **Prasanta Kumar Dash, UAE | Tarek Alkhouri, UAE | Salman Sray Aldeen, UAE**	
14:00 – 14:20	Navigating METex14 Skipping NSCLC – ***Supported by Merck*** **Kaltar Das, UAE**
14:20 – 14:50	**Panel Discussion:** Treatment Options in NSCLC Beyond EGFR AND ALK Moderator: **Akhil Kapoor, India** Panellists: **Sonia Otsmane, UAE | Vijay Patil, India| Vanita Noronha, India Rajiv Kaushal, India | Kumar Prabhash, India | Maroun El Khoury, UAE Fathi Azribi, UAE**
14:50 – 15:05	Reimagining Healthy-Care: The Role of Blood-Based Multi-Cancer Screening in Preventative Oncology Programs – ***Satellite Symposium by Guardant*** **Shaheenah Dawood, UAE**
15:05 – 15:25	ADC – How the options has expanded as options **Vijay Patil, India**
15:25 – 15:45	Geriatric patients – Should we manage differently **Vanita Noronha, India**
15:45 – 16:00	**Q&A**
16:00	**End of Session**

Uro-Oncology Session.

DAY TWO - AGENDA

SUPPORTED BY

ARAB SCHOOL OF UROLOGY

14 November 2026 (Saturday) | **08:30 – 13:00** Hrs GST | **In Person** | **Al Amwaj**

SESSION 1
Precision Oncology in Genitourinary Cancers

Chairperson: **Omer Al Derwish, UAE | Amer Mousa, UAE**

08:30 – 08:35	**Welcome Remarks**
08:35 – 08:50	Prostate Cancer: Advances in PSMA-PET Imaging and Molecular Diagnostics **Mazin Al-Janabi, UAE**
08:50 – 09:05	Prostate Cancer: Management of Biochemical Recurrence and Metastatic Hormone-Sensitive Disease **Jawaher Ansari, UAE**
09:05 – 09:20	Prostate Cancer: PARP Inhibitors and Emerging Combination Therapies in mCRPC **Mohamed Ashour, Kuwait**
09:20 – 09:35	Bladder Cancer: New Treatment Paradigms for High-Risk NMIBC and BCG-Unresponsive Disease **Omer Al Derwish, UAE**
09:35 – 09:50	Bladder Cancer: Contemporary Management of Muscle-Invasive and Metastatic Urothelial Carcinoma **Amer Mousa, UAE**
09:50 – 10:05	RLT Earlier in the Disease Journey: Redefining the Treatment Landscape of Metastatic Prostate Cancer ***- Supported by Novartis*** **Rana Irfan Mahmood, UAE**
10:05 – 10:20	Q&A
10:20 – 10:40	**Coffee Break**

Uro-Oncology Session.

DAY TWO - AGENDA

SESSION 2 **Innovations in Renal Cancer and Multidisciplinary Care** Chairperson: **Muhammad Elmussareh, UAE**	
10:40 – 10:55	Renal Cell Carcinoma: Management of Small Renal Masses, Ablation and Active Surveillance **Sulaiman Al Saadi, Oman**
10:55 – 11:10	Renal Cell Carcinoma: Biomarkers, ctDNA and Future Directions in Personalized Therapy **Amer Mousa, UAE**
11:10 – 11:30	AUA 2026 Highlights: Practice-Changing Updates in Genitourinary Oncology **Muhammad Elmussareh, UAE**
11:30 – 11:50	Translating Evidence to Outcomes in mHSPC - ***Satellite Symposium by JnJ*** **Sonia Otsmane, UAE**
11:50 – 12:05	**Case-Based Discussion:** Challenging Prostate and Bladder Cancer Scenarios Moderator: **Muhammad Elmussareh, UAE** Panellists: **Rana Irfan Mahmood, UAE | Maroun El Khoury, UAE** **Omer Al Derwish, UAE | Amer Mousa, UAE**
12:05 – 12:20	**Case-Based Discussion:** Contemporary Management of Complex Renal Cell Carcinoma Cases Moderator: **Thamir Alkasab, UAE** Panellists: **Muhammad Elmussareh, UAE | Maroun El Khoury, UAE** **Omer Al Derwish, UAE | Amer Mousa, UAE**
12:20 – 13:00	**Lunch Break**

Oncology Nursing Session.

DAY TWO - AGENDA

SUPPORTED BY

EMIRATES ONCOLOGY & HEMATOLOGY NURSING SOCIETY

14 November 2026 (Saturday) | **13:30 – 17:00** Hrs GST | **In Person** | **Al Amwaj**

ONCOLOGY NURSING SESSION

Chairperson: **Rosemary Wasti, UAE**

13:30 – 13:40	**Opening Remarks**
13:40 – 14:10	Emirates Oncology and Haematology Nursing Society **Rosemary Wasti, UAE**
14:10 – 14:30	Mutations Encountered in Acute Lymphoblastic Leukemia Based on Next-Generation Sequencing **Amal Al Haddad, UAE**
14:30 – 14:50	Preparing Oncology Nurses for the Future Building Competency in Advanced Cancer Therapies **Farah Farroukh, UAE**
14:50 – 15:00	Nursing in the Age of Artificial Intelligence: what is NEXT **Alaa Al Abbadi, UAE**
15:00 – 15:15	Sexuality in cancer patients: addressing the elephant in the room **Shyla Sajan, UAE**
15:15 – 15:20	**Q & A**
15:15 – 15:20	**Coffee Break**
15:40 – 16:10	Survivorship in Cancer Patients **Rosemary Wasti, UAE**
16:10 – 16:30	The Evolution of the Cancer Nurse Coordinator: Past, Present, and Future Direction **Sondos Yadak, UAE**
16:30 – 16:40	**Q & A**
16:40 - 17:00	**Closing Remarks**

Palliative Care Session.

DAY TWO - AGENDA

14 November 2026 (Saturday)	13:00 – 17:00 Hrs GST	In Person	Al Noor

SESSION 1 Chairperson: **Doreen Odjidja, UAE**	
13:00 - 13:15	**Welcome and Opening Remarks** **Mona Tareen, UAE**
13:15 – 13:40	More Than Music: Improving Patient Outcomes Through Music Therapy **Sasha McLeod, UAE | Kristal Foster, UAE**
13:40 – 15:10	Whose Well-Being? Rethinking Palliative Care Through Critical and Decolonial Perspectives **Claude Chidiac, UK**
15:10 – 15:30	Palliative Care in the Gulf: Bridging Culture, Compassion, and Clinical Care **Tala Al-Dabbous, Kuwait**
15:30 – 15:50	Words Create Worlds: Your Language Is an Intervention — From Passive Patient to Informed Partner Across the Cancer Pathway **Magda Snowden, UAE**
15:50 – 16:00	**Q & A**
16:00 - 16:15	**Coffee Break & Book Signing with Magda Snowden**
SESSION 2 Chairperson: **Doreen Odjidja, UAE**	
16:15 – 16:35	Real-World Outcomes of Reiki as an Integrative Supportive Care Intervention at a Comprehensive Cancer Center in the MENA Region **Shilpa Kudekar McNeily, UAE**
16:35 – 17:00	Looking Beyond Physical Pain: Exploring Existential Suffering in Palliative Care **Sebastian Rees, UAE**
17:00	**Closing Remarks**

NOW APPROVED

ETCAMAH™
camizestrant
75 mg tablets

For patients with HR+/HER2- aBC, currently on 1L AI + CDK4/6i, upon *ESR1*m emergence[1]

Take charge of your 1L approach

ETCAMAH + CDK4/6i* delivered unprecedented PFS benefit during 1L with a ctDNA-guided switch upon *ESR1*m emergence[2-11]



Stay ahead of *ESR1*m with ctDNA monitoring to enable earlier intervention and sustained control[1,2]

Test patients with **HR+/HER2– aBC** on **AI + CDK4/6i** for ≥6 months to guide treatment decisions[1]

MONITOR
IN TIME

Order a validated liquid biopsy test for *ESR1*m every 3 months[1]

*ESR1*m

- *ESR1*m can emerge as early as 6 months after initiation of AI (and up to 30 months thereafter)[12, †]
- In SERENA-6, ~90% of patients had *ESR1*m detected within 5 tests (n=521)[13]

SWITCH
IN FIRST LINE

Upon *ESR1*m emergence, switch AI for ETCAMAH and continue on CDK4/6i[1, ‡]

ETCAMAH

- ETCAMAH, a next-generation oral SERD, can help prolong time on and benefit from 1L CDK4/6i therapy[1,2]

Monitor for ***ESR1*m** emergence to enable a timely **1L switch to ETCAMAH + CDK4/6i*** to help preserve **disease control and QoL[1,2]**

Therapeutic Indication: ETCAMAH in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1-mutation during first-line endocrine-based therapy.[1]

*In pre- or peri-menopausal women and in men, ETCAMAH plus a CDK4/6 inhibitor should be combined with a luteinizing hormone releasing hormone (LHRH) agonist, in accordance with current clinical practice standards.[1] †Data observed in the PADA-1 trial. ‡SERENA-6 designed to proactively address emerging endocrine resistance to extend time on and benefit of 1L CDK4/6i.[2]

aBC, advanced breast cancer; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; CDK4i, cyclin-dependent kinase 4 inhibitor; ctDNA, circulating tumor DNA; ESR, estrogen receptor; *ESR1*m, estrogen receptor 1 mutation; HR+/HER2-, hormone receptor-positive/human epidermal growth factor receptor 2-negative; 1L, first-line.

References: 1. CAMIESTRANT. Prescribing Information. **2.** Bidard FC, et al. First-line camizestrant for emergent *ESR1* mutations in advanced breast cancer: Final progression-free survival 2 from the phase III SERENA-6 trial. Presented at: 2026 ASCO Annual Meeting; 2026; Chicago, IL. **3.** Kisqali® (ribociclib). Summary of product characteristics. **4.** Ibrance® (palbociclib). Summary of product Characteristics. **5.** Verenios® (abemaciclib).Summary of product characteristics. **6.** Inluriyo® (imlunestrant). Summary of product characteristics. **7.** ARIMIDEX® (anastroole). Summary of product characteristics. **8.** Femara® (letroole). Summary of product characteristics. **9.** Aromasin® (exemestane). Summary of product characteristics. **10.** Tamoxifen. Summary of product characteristics. **11.** FASLODEX® (fulvestrant) Summary of product characteristics. **12.** Cabel L, et al. 1O Kinetics and determinants of blood ESR1 mutation under AI and palbociclib in HR+/HER2- metastatic breast cancer patients in the PADA-1 trial. Presented at: ESMO Breast Cancer Annual Congress; May 14-17, 2025; Munich, Germany. **13.** Turner NC, et al. Camiestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutationsduring first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC): phase 3, double-blind ctDNA-guided SERENA-6 trial. Presented at: 2025 ASCO Annual Meeting; May 30-June 3, 2025; Chicago, IL. Abstract LBA4.

Scan the QR code for the PI and PIL

For Gulf
For Reporting Adverse Events and/or Product Quality Complaints:
Website: https://contactazmedical.astrazeneca.com
E-mail: Patientsafety-azgulf@astrazeneca.com
Call AstraZeneca FZ LLC land line: +97143624888

For Medical Information Enquiries:
Website: https://contactazmedical.astrazeneca.com
E-mail: gulf-medicalinfo@astrazeneca.com
Call AstraZeneca FZ LLC land line: +97143624888

AstraZeneca
AstraZeneca Dubai Science Park,
Tower South, Floor 1706 S, Dubai, UAE
T: +971 4 362 4888

Date of Preparation: June 2026
Date of Expiry: June 2028
Approval code: Z5-9563

ETCAMAH is a trademark of the AstraZeneca group of companies. ©2026 AstraZeneca. All rights reserved.

DAY THREE

15 NOVEMBER 2026

VIRTUAL PROGRAM

EIOC2026
cancercongress.ae

APMEA Molecular Tumor Board.

DAY THREE - AGENDA

15 November 2026 (Sunday) | **10:00 – 13:00** Hrs UAE Time | **Virtual**

APMEA MTB Session

Chairpersons: **Tobias Arkenau, UK | Bashar Zeidan, UAE | Devan Moodley, South Africa**

10:00 – 10:10	**Opening Remarks** **Shaheenah Dawood, UAE**
10:10 – 10:30	Clarity at Diagnosis - Confidence for the Path Forward **George Sledge, USA**
10:30 – 11:00	Molecular Tumor Board – **Gynae Cancer** Moderator: **Hassan Shahryar, UAE** Panel: **Hind El Malik, Qatar | Aref Chehal, UAE | Noureen Saber, UAE** **Aparna Dhar, India | Aref Zribi, Oman**
11:00 – 11:15	Clinical Utility of Comprehensive Genomic Profiling in Advanced Breast Cancer - ***Satellite Symposium by Guardant*** **Hazem Assi, Lebanon**
11:15 – 11:45	Molecular Tumor Board – **Breast Cancer** Moderator: **Joline Lim, Singapore** Panel: **Mastura Yusof, Malaysia | Dalia Elshorbagy, UAE** **Sonia Otsmane, UAE | Aref Chehal, UAE | Amir Abdelazim, Kuwai** **Aparna Dhar, India | Tarkan Yetişyiğit, Bahrain** **Giuseppe Curigliano, Italy | Javier Cortes, Spain | Maroun El Khoury, UAE**
11:45 – 12:30	Molecular Tumor Board – **GI Cancer** Moderator: **Axel Grothey, USA** Panel: **Elizabeth Smyth, UK | Ahmad Al Ghoche, Oman** **Aparna Dhar, India | Ahmad Al Rifai, UAE | Deborah Mukherji, UAE** **Alaaeldin Shablak, Qatar | Jens Samol, Singapor | Husam Marashi, UAE** **Sara Al Bastaki, UAE**
12:30 – 13:00	Molecular Tumor Board – **Lung Cancer** Moderator: **Kumar Prabhash, India** Panel: **Pongwut Danchaivijitr, Thailand | Aparna Dhar, India** **Ammar Madani, Qatar | Hassan Ghazal, UAE | Vanita Noronha, India** **Omshree Shetty, India | Prabhat Malik, India | Maroun El Khoury, UAE**
13:00	**Closing of EIOC 2026**

New Horizons in GYN Cancers Workshop.

DAY ONE - WORKSHOP

Supported by AstraZeneca

13 November 2026 (Friday) | **18:00 – 19:30** Hrs GST | **Al Majlis Meeting Room**

18:00	**Opening Remarks** **Shaheenah Dawood, UAE**
18:00 - 18:30	Interactive Clinical Cases Discussion on The power of PARP inhibitors in First-line maintenance therapy for ovarian cancer Moderator: **Shaheenah Dawood, UAE** Panelists: **Cherian Thampy, UAE | Dima Abdul Jabbar, UAE** **Ramanujam Singarachari, UAE**
18:30 - 18:50	Role of PARPi in Combination with CPI in the Treatment of Endometrial Cancer **Fathi Azribi, UAE**
18:50 - 19:15	Interactive Clinical Cases Moderator: **Shaheenah Dawood, UAE** Panelists: **Hind El Malik, Qatar | Dalia Elshorbagy, UAE | Noureen Saber, UAE**
19:15 - 19:30	**Closing & Remarks**

From First Move to Next Move: Rethinking NSCLC.

DAY TWO - WORKSHOP

Supported by Johnson&Johnson

14 November 2026 (Saturday) | **16:00 – 17:30** Hrs GST | **Al Majlis Meeting Room**

16:00 – 16:10	Priming the Stage **Shaheenah Dawood, UAE**
16:10 – 16:30	Why the First Move Matters: A Look at MARIPOSA Data & Implications **Hassan Shahryar, UAE**
16:30 – 16:50	Why the Next Move Matters: A Look at MARIPOSA-2 Data & Implications **Dalia Elshorbagy, UAE**
16:50 – 17:10	What Good Therapy Management Looks Like **Sonia Otsmane, UAE**
17:10 – 17:30	**Panel Discussion & Open Forum**

Acting Before Progression: ctDNA guided decisions in 1L HR+/HER2- aBC

DAY TWO - WORKSHOP

Supported by AstraZeneca

14 November 2026 (Saturday) | **18:00 - 19:30** Hrs GST | **Al Majlis Meeting Room**

18:00 - 18:05	**Opening Remarks** **Shaheenah Dawood, UAE**
18:05 - 18:15	The Unmet Need in 1L HR+ HER2- aBC **Javier Cortes, Spain**
18:15 - 18:25	SERENA-6 From Trial design to Clinical Meaning **Francois-Clement Bidard, France**
18:25 - 19:30	Panel Discussion Moderator: **Shaheenah Dawood, UAE** Panelists: **Bassel Jallad, UAE | Maroun El Khoury, UAE | Dalia ElShorbagy, UAE** **Ramanujam Singarachari, UAE | Tarkan Yetişyiğit, Bahrain** **Dima Abdul Jabbar, UAE**

Optimizing Treatment for HER2-Low & HER2-Ultralow mBC

DAY TWO - WORKSHOP

Supported by AstraZeneca

14 November 2026 (Saturday) | **19:30 – 21:00** Hrs GST | **Al Majlis Meeting Room**

19:30 – 19:40	Welcome and Introduction **Shaheenah Dawood, UAE**
19:40 – 20:00	Optimizing Treatment for HER2 Low & HER2-Ultralow mBC **Javier Cortes, Spain**
20:00 – 20:25	Case Discussion 1 Moderator: **Fathi Azribi, UAE** Panelists: **Dima Abdul Jabbar, UAE | Bassel Jallad, UAE** **Tarkan Yetisyigit, Bahrain | Javier Cortes, Spain**
20:25 – 20:50	Case Discussion 2 Moderator: **Dalia Elshorbagy, UAE** Panelists: **Husam Marashi, UAE | Hala Abdellatif, UAE** **Suhaila Al Farsi, Oman | Javier Cortes, Spain**
20:50 – 21:00	**Closing Remarks**

Acknowledgement.

MAIN SPONSORS

AstraZeneca Lilly MSD NOVARTIS

PLATINUM SPONSORS

hikma. GUARDANT Roche

GOLD SPONSORS

Bristol Myers Squibb EXACT SCIENCES is now ABBOTT ميديكلينيك MEDICLINIC

Johnson&Johnson Stemline A Menarini Group Company

HEALTHCARE PARTNERS

المستشفى الأمريكي AMERICAN HOSPITAL

SILVER SPONSORS

abbvie AMGEN Biocon GILEAD Oncology Juniper Biologics

KYOWA KIRIN NEWBRIDGE PHARMACEUTICALS PHARMALINK

SUPPORT SPONSORS

Advanced Care Oncology Center مركز ادفانس كير لتشخيص و علاج الأورام astellas CARIS LIFE SCIENCES firebird biologics

GICC مركز الخليج الدولي للأورام Glenmark Oncology MERCK

EXHIBITORS

BAYER BeOne DNA GTx natera

CONTINUING THE JOURNEY
SEE YOU IN 2027!

SAVE THE DATE

15 - 17 October, 2027
Dubai, United Arab Emirates

cancercongress.ae

INDEX Holding Headquarters, Road # D-62, Opposite Nad Al Hamar
P.O. Box: 13636, Dubai, UAE | Tel: +971 4 520 8888, Fax: +971 4 338 4193
Email: info@cancercongress.ae, Website: cancercongress.ae